Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy
NCT ID: NCT03279900
Last Updated: 2018-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
101 participants
OBSERVATIONAL
2017-10-02
2018-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia
NCT03255668
Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL
NCT05811845
Study of the Medullary Microenvironment in Acute Childhood Leukemia
NCT05792007
Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
NCT03627208
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT00343369
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received chemotherapy maintenance phase based on Indonesian protocol of ALL - 2013
Exclusion Criteria
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indonesia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dewi Selvina Rosdiana
Researcher at Department of Pharmacology and Therapeutics Faculty of Medicine University of Indonesia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rianto Setiabudy, Professor
Role: STUDY_DIRECTOR
Departemen of Pharmacology and therapeutics, FMUI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cipto Mangunkusomo hospital
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IndonesiaUI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.